Edition:
United States

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

9.33USD
14 Dec 2017
Change (% chg)

$1.25 (+15.47%)
Prev Close
$8.08
Open
$8.47
Day's High
$9.86
Day's Low
$8.22
Volume
1,221,910
Avg. Vol
385,203
52-wk High
$9.86
52-wk Low
$0.82

Latest Key Developments (Source: Significant Developments)

Marinus Pharmaceuticals files for mixed shelf of up to $200 mln
Tuesday, 31 Oct 2017 04:39pm EDT 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​.  Full Article

Marinus Pharmaceuticals qtrly loss per share $0.15‍​
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results.Marinus Pharmaceuticals Inc - ‍"believes" cash, cash equivalents and investments as of Sept 30, 2017 are adequate to fund operations into 2020​.Marinus Pharmaceuticals Inc qtrly loss per share $0.15‍​.Marinus-Initiating Phase 2 feasibility study with ganaxolone iv in patients with refractory status epilepticus, data expected in 2018‍​.  Full Article

Bain Capital Life Sciences Fund reports 14.4 pct passive stake in Marinus Pharmaceuticals
Thursday, 28 Sep 2017 04:44pm EDT 

Sept 28 (Reuters) - Marinus Pharmaceuticals Inc :Bain Capital Life Sciences Fund L.P reports 14.4 percent passive stake in Marinus Pharmaceuticals Inc as of Sept 19, 2017 - SEC filing.  Full Article

Marinus Pharmaceuticals announces pricing of public offering of common stock
Friday, 15 Sep 2017 07:30am EDT 

Sept 15 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 9.33 million common shares priced at $3.75 per share.  Full Article

Marinus Pharmaceuticals announces public offering of common stock
Thursday, 14 Sep 2017 04:01pm EDT 

Sept 15 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals Inc announces public offering of common stock.Marinus Pharmaceuticals Inc - intends to use net proceeds of offering to advance clinical development of ganaxolone, among others.  Full Article

Marinus announces successful clinical trial results
Monday, 11 Sep 2017 07:30am EDT 

Sept 11 (Reuters) - Marinus Pharmaceuticals Inc :Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone.Marinus Pharmaceuticals Inc - ‍ganaxolone was generally safe and well-tolerated with no serious adverse events​.Marinus Pharma- 1 child has not yet reached 26-week visit, 2 children discontinued prior to completing 26-week treatment due to lack of efficacy​.Marinus Pharmaceuticals Inc - ‍there have been no adverse event reports of somnolence or dizziness​.Marinus Pharmaceuticals Inc - has prioritized CDKL5 disorder as lead pediatric orphan program for advancement into later stage clinical development​.‍​.  Full Article

EecoR1 Capital reports 12.2 pct passive stake in Marinus Pharmaceuticals
Tuesday, 8 Aug 2017 02:26pm EDT 

Aug 8 (Reuters) - Marinus Pharmaceuticals Inc :EecoR1 Capital LLC​ report a 12.2 percent passive stake in Marinus Pharmaceuticals Inc as of August 4, 2017 - SEC filing.  Full Article

Marinus Pharmaceuticals posts quarterly loss of $0.21 per share
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Marinus Pharmaceuticals Inc :Provides business update and reports second quarter 2017 financial results.On-track to initiate two additional Phase 2 trials later this year.Expect to announce top-line data from Phase 2 trial evaluating children with CDKL5 disorder this quarter.Believes cash, cash equivalents, investments, as of June 30, are adequate to fund operations into Q4 of 2018.At June 30, 2017, company had cash, cash equivalents and investment balances of $20.3 million.Qtrly net loss per share of common stock-basic and diluted $0.21.Data from studies in rare pediatric epilepsies and severe postpartum depression expected in H2 2017.  Full Article

Marinus Pharmaceuticals says Granite Point reports a 9.75 percent passive stake in Marinus- SEC Filing
Tuesday, 18 Jul 2017 04:07pm EDT 

July 18 (Reuters) - Marinus Pharmaceuticals Inc :Granite point capital management lp reports a 9.75 percent passive stake in marinus pharmaceuticals inc as of july 6, 2017 - sec filing.  Full Article

Marinus Pharmaceuticals says James Flynn reports 9.98 percent passive stake in Marinus as of July 14, 2017 - sec filing
Monday, 17 Jul 2017 05:17pm EDT 

July 17 (Reuters) - Marinus Pharmaceuticals Inc :James E. Flynn reports a 9.98 percent passive stake in Marinus Pharmaceuticals Inc as of July 14, 2017 - Sec Filing.  Full Article

BRIEF-Marinus Pharmaceuticals files for mixed shelf of up to $200 mln

* Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​ Source text: [http://bit.ly/2z23P1a] Further company coverage: